The Role of Immunotherapy in Multiple Myeloma.

Pharmaceuticals (Basel, Switzerland) (2016-01-20)
Mehmet Kocoglu, Ashraf Badros
ABSTRACT

Multiple myeloma is the second most common hematologic malignancy. The treatment of this disease has changed considerably over the last two decades with the introduction to the clinical practice of novel agents such as proteasome inhibitors and immunomodulatory drugs. Basic research efforts towards better understanding of normal and missing immune surveillence in myeloma have led to development of new strategies and therapies that require the engagement of the immune system. Many of these treatments are under clinical development and have already started providing encouraging results. We, for the second time in the last two decades, are about to witness another shift of the paradigm in the management of this ailment. This review will summarize the major approaches in myeloma immunotherapies.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Graphene ink in water, inkjet printable
Sigma-Aldrich
Anti-IL6 antibody produced in rabbit, IgG fraction of antiserum, buffered aqueous solution
Sigma-Aldrich
Anti-IL6 high affinity antibody, Mouse monoclonal, clone IL6-2A3, purified from hybridoma cell culture
Sigma-Aldrich
Anti-IL6 high affinity antibody, Mouse monoclonal, clone IL6-4G1, purified from hybridoma cell culture
Sigma-Aldrich
SILuRich Anti-IL6 MAb, biotin conjugated, clone IL6-4G1, purified from hybridoma cell culture

Social Media

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon

MilliporeSigma

Research. Development. Production.

We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

Reproduction of any materials from the site is strictly forbidden without permission.